Heparin Ukonserveret Sad (Heparin Sodium)

Heparin Ukonserveret Sad is indicated for several antithrombotic indications where inhibition of clot formation is required.

• Prevention and treatment of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Prophylaxis of DVT and PE in patients undergoing orthopedic, abdominal or cancer surgery.
• Management of acute coronary syndromes such as unstable angina or non‑ST elevation myocardial infarction.
• Treatment of disseminated intravascular coagulation (DIC) when anticoagulation is appropriate.
• Use during extracorporeal circulation procedures, such as cardiopulmonary bypass, to maintain circuit patency.
• Adjunct anticoagulation in patients receiving thrombolytic therapy to reduce re‑occlusion risk.

Heparin Ukonserveret Sad may be associated with a range of adverse effects, most of which are related to its anticoagulant activity.

Common

• Minor bleeding at the injection site, such as oozing or small ecchymosis, which usually resolves without intervention.
• Bruising or formation of a small hematoma around the injection area, often transient.
• Elevated activated partial thromboplastin time (aPTT) laboratory value, indicating increased anticoagulant effect.
• Transient gastrointestinal discomfort, nausea, or vomiting that is mild and self‑limited.

Serious

• Major hemorrhage, including life‑threatening intracranial bleeding or severe gastrointestinal bleeding, requiring urgent medical attention.
• Heparin‑induced thrombocytopenia (HIT), an immune‑mediated reaction that can cause a rapid drop in platelet count and paradoxical thrombosis.
• Severe allergic reactions such as widespread rash, urticaria, angioedema, or anaphylaxis, which may necessitate immediate treatment.
• Osteoporosis or bone demineralization with prolonged therapy, particularly concerning in long‑term or pregnant patients.

When prescribing Heparin Ukonserveret Sad, clinicians should consider several precautions to minimize the risk of complications.

• Assess baseline bleeding risk and coagulation parameters before initiating therapy.
• Monitor aPTT or anti‑Xa levels regularly to maintain therapeutic range.
• Use caution in patients with a history of heparin‑induced thrombocytopenia or known hypersensitivity.
• Adjust dose or avoid use in individuals with severe renal impairment, as clearance may be reduced.
• Consider alternative anticoagulation during pregnancy only when benefits outweigh potential fetal risks.
• Avoid concurrent use with other anticoagulants or antiplatelet agents unless clinically justified.

Heparin Ukonserveret Sad can interact with other medicines that affect hemostasis or drug metabolism.

Avoid

• Concurrent use with other systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) due to additive bleeding risk.
• Combination with potent antiplatelet agents (e.g., clopidogrel, aspirin) unless closely monitored.
• Co‑administration with fibrinolytic therapy (e.g., alteplase) without appropriate clinical justification.

Use with caution

• Concomitant use of non‑steroidal anti‑inflammatory drugs (NSAIDs) or corticosteroids, which may increase bleeding tendency.
• Concurrent administration of drugs that reduce platelet function (e.g., thienopyridines) requiring careful monitoring.
• Use with renal‑clearing agents in patients with impaired kidney function, as heparin clearance may be affected.